Oncolytics Biotech® Announces Investigator Sponsored Phase II Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

Oncolytics Biotech® Inc announced a new investigator-sponsored triple-negative breast cancer study to be managed by Rutgers Cancer Institute of New Jersey. The phase II trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte’s anti-PD-1 checkpoint inhibitor retifanlimab in patients with unresectable locally advanced or metastatic TNBC.
[Oncolytics Biotech]
Press Release
Bookmark

No account yet? Register

Share

Mechanical Strain Induces Phenotypic Changes in Breast Cancer Cells and Promotes Immunosuppression in the Tumor Microenvironment

Researchers demonstrated that exposure to mechanical strain promoted invasive and pro-tumorigenic phenotypes in breast cancer cells, indicating that mechanical strain could impact the growth and proliferation of cancer cell, alter exosome production by breast cancer, and induce immunosuppression in the tumor microenvironment by dampening anti-tumor immunity.
[Laboratory investigation]
[zotpress userid=’6606345′ items=’6TBDE2XT’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Genentech’s Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People with Early Triple-Negative Breast Cancer

Genentech announced that the Phase III IMpassion031 study, evaluating Tecentriq® in combination with chemotherapy in comparison to placebo plus chemotherapy, met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer, regardless of PD-L1 expression.
[Genetech]
Press Release
Bookmark

No account yet? Register

Share

Molecular Characterization of Circulating Tumor Cells Identifies Predictive Markers for Outcome in Primary, Triple‐Negative Breast Cancer Patients

mRNA profiles of circulating tumor cells were analysed in patients with triple‐negative breast cancer before and after therapy to identify additional treatment options.
[Journal of Cellular and Molecular Medicine]
[zotpress userid=’1254621′ items=’IC9SMBVI’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-Negative Breast Cancer Cells by Repressing the EGFR gene

Investigators report that krüppel-like factor 4 was a major determinant of epidermal growth factor receptor expression and activity in TNBC cells.
[Breast Cancer Research]
[zotpress items='{6606345:B5K6AG7X}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Antitumor Effect of a WEE1 Inhibitor and Potentiation of Olaparib Sensitivity by DNA Damage Response Modulation in Triple-Negative Breast Cancer

Scientists investigated the antitumor effects of a WEE1 inhibitor and the mechanisms responsible for its effects on the cell cycle and DNA repair pathway as a monotherapy and in combination with a PARP inhibitor, an ATR inhibitor, and a DNA damage-inducing agent in six TNBC cell lines and in a Balb/c athymic nude mouse xenograft model.
[Scientific Reports]
[zotpress items='{6606345:3WSBRMYU}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer

By immunohistochemistry scientists observed up-regulation of humanin in triple negative breast cancer biopsies when compared to mammary gland sections from healthy donors.
[Scientific Reports]
[zotpress items='{6606345:ABHFTY2L}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Differential Functions of ERK1 and ERK2 in Lung Metastasis Processes in Triple-Negative Breast Cancer

Investigators provided evidence supporting the notion that ERK1 and ERK2 have functionally distinct properties and that ERK2, not ERK1, primarily contributed to lung metastasis in a riple negative breast cancer mouse model.
[Scientific Reports]
[zotpress items='{6606345:YCVVCD4Q}’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Opposing Functions of BRD4 Isoforms in Breast Cancer

Investigators showed, by isoform-specific knockdown and endogenous protein detection, along with transgene expression, the less abundant bromodomain-containing protein 4 short isoform was oncogenic while bromodomain-containing protein 4 long isoform was tumor-suppressive in breast cancer cell proliferation and migration, as well as mammary tumor formation and metastasis.
[Molecular Cell]
[zotpress items='{6606345:TZ964V38}’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Destabilization of β-Catenin and RAS by Targeting the Wnt/β-Catenin Pathway as a Potential Treatment for Triple-Negative Breast Cancer

Scientists found that both β-catenin and RAS, as well as epidermal growth factor receptor, were overexpressed and correlated with one another in tumor tissues of TNBC patients.
[Experimental and Molecular Medicine]
[zotpress items='{6606345:566WVA2N}’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

DNMT1: A Key Drug Target in Triple-Negative Breast Cancer

The author presents and discusses the oncogenic functions rendered by DNA methyltransferase 1 (DNMT1) in triple negative breast cancer, and DNMT1 inhibitors targeting TNBC cells.
[Seminars in Cancer Biology]
[zotpress items='{6606345:34CX7T5L}’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share